Rewiring the Brain… Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix
Companies To Watch: Spinogenix
Addressing Root Causes of Brain Disorders with Innovative Therapeutics
Enhancing Neurodegenerative Care: Dialogue Exchange with Stella Sarraf of Spinogenix
To Reverse Aging’s Clock, Adjust the Cell’s Machinery
Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease
Sydney Alzheimer’s Patients Will Be The First to Trial a New Drug
Hope Pill Will Turn Tables on Dementia
Synapse-regenerating drug could reverse decline in Alzheimer’s
FDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302
Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS
World-first MND drug trial offers hope to those living with the disorder
FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS
FDA clears investigational new drug application for clinical trial of ALS pill
Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trial
FDA grants IND clearance for Spinogenix’s ALS treatment trial
Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials
Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment
A Promising Treatment for MND
A new drug that could reverse the worst symptoms of MND is about to be trialled in Australia.
Novel motor neurone disease, MND, drug SPG302 to be trialled in Australia
ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix
Spinogenix Lands $4M in New Federal Grants
Spinogenix awarded $1M to advance clinical testing of SPG302
Spinogenix: World-first trial giving hope to those living with MND
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia | ALS News Today
Human Trial Gives Hope to MND Patients
Australians with MND will be the first in the world to trial a new drug
World first drug trial for MND treatment | Sky News Australia
A world-first trial for a new drug that may slow the progression of motor neurone disease is set to begin in Melbourne.
World first drug trial for MND treatment | The Australian
World first drug trial for MND treatment
FDA grants orphan designation to Fragile X syndrome therapeutic
Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome
FDA clears Phase 2 trial of oral SPG601 in men with fragile X
FDA clears investigational new drug application for Fragile X treatment
Two major breakthroughs in Fragile X Syndrome treatments
Spinogenix’s Investigational New Drug Application for Novel Treatment for Fragile X Syndrome Cleared to Begin Phase II Trial
First Synaptic Regenerative Therapy for Schizophrenia Under Investigation
Synapse-restoring pill set for human trials as novel schizophrenia treatment
